Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.370
+0.008 (2.12%)
At close: Apr 28, 2026, 4:00 PM EDT
0.364
-0.006 (-1.67%)
Pre-market: Apr 29, 2026, 7:23 AM EDT
Cosmos Health Revenue
In the year 2025, Cosmos Health had annual revenue of $65.27M with 19.93% growth. Cosmos Health had revenue of $19.70M in the quarter ending December 31, 2025, with 38.52% growth.
Revenue (ttm)
$65.27M
Revenue Growth
+19.93%
P/S Ratio
0.29
Revenue / Employee
$438,066
Employees
149
Market Cap
18.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.27M | 10.85M | 19.93% |
| Dec 31, 2024 | 54.43M | 1.05M | 1.97% |
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| McKesson | 397.96B |
| Cencora | 325.78B |
| Cardinal Health | 244.67B |
| Henry Schein | 13.18B |
| Accendra Health | 2.76B |
| 111, Inc. | 1.80B |
| EDAP TMS | 70.53M |
| Synergy CHC | 30.38M |
COSM News
- 7 days ago - Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products - Accesswire
- 8 days ago - Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio - Accesswire
- 11 days ago - Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health - Accesswire
- 12 days ago - Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% - Accesswire
- 13 days ago - Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments - Accesswire
- 15 days ago - Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units - Accesswire
- 18 days ago - Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months - Accesswire
- 20 days ago - Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction - Accesswire